DUB Therapeutics is a pre-clinical biotechnology startup developing proprietary RNAi technology addressing an unmet need in fibrotic disease(s). Our lead clinical indication addresses the potential of scarring/fibrosis in ocular tissue, the cornea, a model tissue for the study of fibrosis. We are leveraging this orphan disease as proof-of-concept for program expansion across a broad range of therapeutic interests. As the therapeutic target exists in the pathological pathway in all tissues, our larger vision is to expand our asset as a pipeline therapeutic, adopting tissue specific therapeutic intervention to improve the quality of life for patients suffering from fibrosis. We were awarded a Direct to Phase II NIH SBIR in 2023 and completed an FDA INTERACT meeting in December 2024 where we reached agreement for regulatory development with the FDA through Phase I/IIa Clinical Trials. Our self-delivering siRNA (sdRNA) technology is patented, includes an international PCT with completed FTO search confirming IP jurisdiction. DUB Tx has solicited multiple bids for Phase I/II clinical development and expects to dose the first patient Q4 of 2026.